Comparison of the glucose dependency of glucagon-like peptide-1(7-37) and glyburide in vitro and in vivo

Metabolism: Clinical and Experimental

Volumn 45, Issue 3, 1996, Pages 404-409

  Hargrove, Diane M ^a,b   Nardone, Nancy A ^a   Persson, Lorna M ^a   Andrews, Kim M ^a   Shepherd, Kandace L ^a   Stevenson, Ralph W ^a   Parker, Janice C ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 [7-37]; GLUCOSE; INSULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RELEASE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS ISLET; PRIORITY JOURNAL; RAT;

EID: 0029886502     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90297-8     Document Type: Article

References (28)

1. Mojsov S, Kopczynski MG, Habener JF: Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem 265:8001-8008, 1990
2. Ørskov C, Rabenhøj L, Wettergren A, et al: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535-539, 1994
3. Fridolf T, Bottcher G, Sundler F, et al: GLP-1 and GLP-1(7-36)amide: Influences on basal and stimulated insulin and glucagon secretion in the mouse. Pancreas 6:208-215, 1991
4. Habener JF: The incretin notion and its relevance to diabetes. Endocrinol Metab Clin North Am 22:775-794, 1993
5. Weir GC: Glucagon-like peptide-1 (GLP-1): A piece of the incretin puzzle. J Clin Invest 95:1, 1995
6. Wang Z, Wang RM, Owji AA, et al: Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 95:417-421, 1995
7. Drucker DJ, Philippe J, Mojsov S, et al: Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84:3434-3438, 1987
8. Goke R, Wagner B, Fehmann H-C, et al: Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1(7-36) amide on the rat pancreas. Res Exp Med 193:97-103, 1993
9. Schmid R, Schusdziarra V, Aulehner R, et al: Comparison of GLP-1(7-36 amide) and GIP on release of somatostatin-like immunoreactivity and insulin from the isolated rat pancreas. Z Gastroenterol 28:280-284, 1990
10. Siegel EG, Schulze A, Schmidt WE, et al: Comparison of the effect of GIF and GLP-1(7-36 amide) on insulin release from rat pancreatic islets. Eur J Clin Invest 22:154-157, 1992
11. Weir GC, Mojsov S, Hendrick GK, et al: Glucagonlike peptide 1(7-37) actions on endocrine pancreas. Diabetes 38:338-342, 1989
12. Zawalich WS, Zawalich KC, Rasmussen H: Influence of glucagon-like peptide-1 on β cell responsiveness. Regul Pept 44:277-283, 1993
13. Goke R, Conlon JM: Receptors for glucagon-like peptide-1(7-36) amide on rat insulinoma-derived cells. J Endocrinol 116:357-362, 1988
14. Ørskov C, Neilsen JH: Truncated glucagon-like peptide-1 (proglucagon 78-107 amide), an intestinal insulin-releasing peptide, has specific receptors on rat insulinoma cells (RIN 5AH). FEBS Lett 229:175-178, 1988
15. Ørskov C, Poulsen SS: Glucagon-like peptide-1-(7-36)-amide receptors only in islets of Langerhans: Autoradiographic survey of extracerebral tissues in rats. Diabetes 40:1292-1296, 1991
16. Thorens B: Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 89:8641-8645, 1992
17. Elahi D, McAloon-Dyke M, Fukagawa NK, et al: The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1(7-37) in normal and diabetic subjects. Regul Pept 51:63-74, 1994
18. Faulkner A, Pollock HT: Effects of truncated glucagon-like peptide-1 on the responses of starved sheep to glucose. J Endocrinol 129:55-58, 1991
19. Gutniak M, Ørskov C, Holst JJ, et al: Antidiabetogenic effect of glucagon-like peptide-1(7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322, 1992
20. Hargrove DM, Nardone NA, Persson LM, et al: Glucose dependent action of glucagon-like peptide-1(7-37) in vivo during acute or chronic administration. Metabolism 44:1231-1237, 1995
21. Hendrick GK, Gjinovci A, Baxter LA, et al: Glucagon-like peptide-1-(7-37) suppresses hyperglycemia in rats. Metabolism 42:1-6, 1993
22. Kawai K, Suzuki S, Ohashi S, et al: Effects of truncated glucagon-like peptide-1 on pancreatic hormone release in normal conscious dogs. Acta Endocrinol (Copenh) 123:661-667, 1990
23. Kreymann B, Williams G, Ghatei MA, et al: Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 2:1300-1304, 1987
24. Nathan DM, Schreiber E, Fogel H, et al: Insulinotropic action of glucagonlike peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276, 1992
25. Nauck MA, Heimesaat MM, Ørskov C, et al: Preserved incretin activity of glucagon-like peptide 1[7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307, 1993
26. Ørskov C, Wettergren A, Holst JJ: Biological effects and metabolic rates of glucagonlike peptide-17-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42:658-661, 1993
27. Lacy PE, Kostianovsky M: Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16:35-39, 1967
28. Holz GG IV, Kuhtreiber WM, Habener JF: Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 361:362-365, 1993